Enliven Therapeutics, Inc (ELVN) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ELVN Hot Sheet
Join SI Premium – FREE
Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q4 EPS of ($0.48), $0.02 worse than the analyst estimate of ($0.46).
For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Datadog shares drop on weak Q4 revenue outlook
- United States Oil Fund (USO) call put ratio 1.2 calls to 1 put as share price down 2.5%
- RxSight Inc. (RXST) PT Lowered to $5 at Stifel
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
